Sunday

September 17

19.00 - 21.30

Get together

Monday

September 18

09.00 - 09.45

Keynote Speaker David Thomas, Garvan Institute of Medical Research, Australia
Omico: Australia's Genomic Cancer Medicine Centre (40 + 5 min)

Session 1: Molecular Pathology & MTBs

Chair: Hege G. Russnes

09.45 - 10.15

Funda Meric-Bernstam, MD Anderson Cancer Centre, USA

Implementing decision support for precision oncology (25 + 5 min)

10.15 - 10.30

Tyler Seibert, University of California San Diego, USA:

Clinical and genomic prediction of lethal prostate cancer (10 + 5 min)

10.30 - 11.00

Maud Kamal, Institut Curie, Paris

Molecular tumor boards & treatment algorithms in Oncology: Institut Curie Experience (25 + 5 min)

11.00 - 11.15

Pitt Niehusmann, Oslo University Hospital, Norway:

Outcome for CNS tumor patients within the IMPRESS-Norway trial (10 + 5 min)

11.15 - 11.45

Lynette Sholl, Dana-Farber / Harvard Cancer Center, USA

Integrated tumor and germline profiling for cancer patients: challenges and benefits (25 + 5 min)

12.00 - 13.00

Lunch

13.00 - 14.55

Poster Session

15.00 - 15.30

Keynote Speaker Francesco Pignatti, European Medicines Agency (EMA): Pan-cancer/Histology-agnostic drug development (25 + 5 min)

Session 2: Clinical Study Designs

Chair: Åslaug Helland

15.30 - 16.00

Christophe Le Tourneau, Institut Curie, Paris

Precision medicine trials in oncology (25 + 5 min)

16.00 - 16.15

Anita Sveen, Oslo University Hospital, Norway

Functional oncology of metastatic colorectal cancer in the context of tumor heterogeneity (10 + 5 min)

16.15 - 16.45

Emile Voest, NCI, The Netherlands

Next generation precision medicine trials: a paradigm shift (25 + 5 min)

16.45 - 17.00

Guro Giskeødegård, NTNU, Norway:

Changes in serum metabolic profiles during breast cancer treatment with aromatase inhibitors (10 + 5 min)

17.00 - 17.30

Richard Schilsky, University of Chicago, USA

The ASCO TAPUR Study: Learning from precision medicine in practice (25 + 5 min)

19.30

Aperitif in the reception area

20.00

Dinner

Tuesday

September 19

08.30 - 09.15

Keynote Speaker Gordon Mills, Knight Cancer Institute, OHSU, USA:
Targeting adaptive responses in cancer through SMMART clinical trials (40 + 5 min)

Session 3: Health Economics, Implementation & Policies

Chair: Gro Live Fagereng

09.15 - 09.45

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, CZ Health Insurance, The Netherlands

Keeping pace with advances in Precision Medicine: a payer's perspective (25 + 5 min)

09.45 - 10.00

Katarina Steen Carlsson, The Swedish Institute for Health Economics, Sweden

Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them? (10 + 5 min)

10.00 - 10.30

Bettina Ryll, Stockholm School of Economics, Sweden

Precision medicine : connecting precision medicine ecosystems across Europe (25 + 5 min)

10.30 - 10.45

Bjørn Hofmann, University of Oslo, Norway

Precision cancer medicine – merging clinical treatment and research: epistemic and ethical benefits and challenges with precision cancer medicine (10 + 5 min)

10.45 - 11.15

Monika Frenzel, French National Research Agency

The personalized medicine journey (25 + 5 min)

11.30 - 12.30

Lunch

Session 4: Scaling of Precision Medicine Ecosystems

Chair: Sigbjørn Smeland

12.30 - 13.00

Jesus Garcia-Foncillas, Jiménez Diaz Foundation University Hospital, Madrid, Spain

Clinical research in targeted therapies in low frequency alterations (25 + 5 min)

13.00 - 13.15

Sigve Nakken, Oslo University Hospital, Norway:

Toward improved matching between cancer patients and clinical trials through automatic knowledge mining of unstructured clinical trial records (10 + 5 min)

13.15 - 13.45

Benedikt Westphalen, LMU Munich, Germany

Sustainable scaling of precision oncology - in or out of reach? (25 + 5 min)

13.45 - 14.00

Kadri Toome, Tartu University Hospital, Estonia:

Molecular profiling of solid tumours using next generation sequencing to detect actionable molecular markers in routine clinical practice – Estonian experience (10 + 5 min)

14.00 - 14.30

Coffee Break

Session 5: The growing ecosystem of DRUP-like clinical trials and European-wide initiatives PCM4EU & PRIME-ROSE

Chair: Kjetil Taskén

14.30 - 14.50

Hans Gelderblom, Leiden University Medical Centre, The Netherlands

The DRUP Trial (20 min)

14.50 - 15.00

Åslaug Helland, Oslo University Hospital, Oslo, Norway

The IMPRESS-Norway Trial (10 min)

15.00 - 15.10

Kristoffer Staal Rohrberg, Rigshospitalet, Copenhagen, Denmark

The ProTarget Trial (10 min)

15.10 - 15.20

Katriina Jalkanen, Helsinki University Hospital, Finland

The FINPROVE Trial (10 min)

15.20 - 15.30

Loic Verlingue, Centre Léon Bérard, Lyon, France

The MOSTPlus Trial (10 min)

15.30 - 15.40

Matthew Krebs, University of Manchester, UK

The DETERMINE Trial (10 min)

15.40 - 15.50

Maeve Lowery, Trinity College Dublin and St James Hospital, Ireland

The PROGRESS Trial (10 min)

15.50 - 16.05

Kjetil Taskén, Oslo University Hospital, Norway

EU-projects PCM4EU & PRIME-ROSE (15 min)

16.10 - 16.40

Panel debate / Q&A (speakers +Edvard Abel and Julio Oliveira)

16.40 - 16.50

Concluding Remarks

Nordic Precision Cancer Medicine

An Acta Oncologica Conference

The overarching theme of this two-day conference is precision cancer medicine. Internationally renowned speakers will give scientific updates as well as updates on collaborative initiatives and implementation of precision cancer medicine across the Nordics and other European countries. Furthermore, patient benefit and visions for the future, including standard health care, is on the agenda.

NPCM 2023

An Acta Oncologica Conference

Pages:

Home
Program
Topics
Speakers
Abstract
Practical